A5037331991- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Pulmonary Hypertension Research and Treatments
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiovascular and exercise physiology
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Issues in Pregnancy
- Takotsubo Cardiomyopathy and Associated Phenomena
- Diabetes Treatment and Management
- Cardiac Structural Anomalies and Repair
- Congenital Heart Disease Studies
- Cardiovascular Effects of Exercise
- Acute Myocardial Infarction Research
- Cardiomyopathy and Myosin Studies
- Cardiac Valve Diseases and Treatments
- Systemic Sclerosis and Related Diseases
- Venous Thromboembolism Diagnosis and Management
- Hemodynamic Monitoring and Therapy
- Cardiac tumors and thrombi
- Pericarditis and Cardiac Tamponade
- Adipokines, Inflammation, and Metabolic Diseases
- Potassium and Related Disorders
Ospedali Riuniti di Foggia
2016-2025
University of Foggia
2016-2025
Casa Sollievo della Sofferenza
2025
Istituti di Ricovero e Cura a Carattere Scientifico
2025
Ospedale Garibaldi
2024
Azienda Ospedaliera di Perugia
2023
Ospedale Buccheri la Ferla Fatebenefratelli
2023
Ospedale Santa Maria della Misericordia di Udine
2023
Ospedale Civile di Venezia
2023
University of Pisa
2014-2022
Rationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), but the effects this approach on risk reduction and vascular resistance (PVR) are not known.Objectives: To test hypothesis that a low-risk status would be determined by PVR patients with PAH treated upfront drugs.Methods: The study enrolled 181 treatment-naive (81% idiopathic) follow-up right heart catheterization at 6 months (interquartile range, 144–363 d) after endothelin...
Heart failure (HF) represents a significant global health challenge, characterized by high morbidity and mortality rates, imposes considerable burdens on healthcare systems patient quality of life. Traditional management strategies, primarily relying clinical assessments standard biomarkers like natriuretic peptides, face limitations due to the heterogeneity HF. This review aims delve into evolving landscape non-natriuretic transformative potential omics technologies, underscoring their...
Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection cardiotoxicity follow-up prognostic assessment cancer patients. In this literature review, we aim at describing current state knowledge on meaning usefulness patients with cancer; analyzing intricate relationship between disease (especially HF) how...
<h3>Background</h3> In hypertrophic cardiomyopathy (HCM), most of the factors associated with risk sudden cardiac death (SCD) are also involved in pathophysiology exercise limitation. The present multicentre study investigated possible ability cardiopulmonary test improving contemporary strategies for SCD stratification. <h3>Methods</h3> A total 623 consecutive outpatients HCM, from five tertiary Italian HCM centres, were recruited and prospectively followed, between September 2007 April...
Background:Heart failure (HF) progression and its complications represent major emergent concerns in hypertrophic cardiomyopathy (HCM). We investigated the possible adjunctive role of cardiopulmonary exercise testing (CPET) predicting HF-related events. An exercise-derived risk model, theHYPertrophicExercise-derivedRiskHF(HYPERHF), has been developed.
Pulmonary arterial hypertension is a complex pathology whose etiology still not completely well clarified. The pathogenesis of pulmonary involves different molecular mechanisms, with endothelial dysfunction playing central role in disease progression. Both individual genetic predispositions and environmental factors seem to contribute its onset. To further understand the relationship between try development future therapies, we report comprehensive updated review on function hypertension.
Pulmonary arterial hypertension (PAH) is a rare subtype of group 1 pulmonary (PH) diseases, characterized by high artery pressure leading to right ventricular dysfunction and potential life-threatening consequences. PAH involves complex mechanisms: vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, oxidative stress, fibrosis, RV cellular hypoxia, metabolic imbalance, thrombosis. These mechanisms are mediated several pathways, involving molecules like nitric oxide...